AIDS Treat News. 1999 Jan 8;(No 310):6. Unique Identifier : AIDSLINE AIDS/20700012
James JS
Abstract: The problems that occurred during the development process of abacavir and the limitations of the data that resulted from that process can indicate ways to improve future research. For instance, researchers need to explore how to design a study with more far-reaching results. Also, more studies are needed about the mechanisms of how new drugs work instead of just whether or not they work. Several years ago, the FDA evaluated their drug approval process in order to design a more efficient system. Since that process concentrates more on the end stages of drug development, another evaluation is needed to improve the design of large clinical trials that occur during the early stages of drug development.
Copyright © 2000 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .